Cencora - Q2 FY2026 Earnings Analysis

Performance Highlights

Cencora reported Q2 FY2026 revenue of $78.4 billion, a 3.9% increase versus the $75.5 billion recorded in the prior-year quarter, with gross profit expanding to $3.6 billion from $3.1 billion. Diluted EPS surged to $8.40 from $3.68, though reported net income of $1.6 billion was meaningfully inflated by a $1.09 billion pre-tax remeasurement gain tied to the step-up acquisition of OneOncology completed on February 2, 2026. The U.S. Healthcare Solutions segment remained the primary revenue engine, benefiting from continued specialty pharmaceutical volume growth including contributions from newly consolidated OneOncology practices, while International Healthcare Solutions provided steady incremental support. Gross margin improvement reflects favorable product and customer mix as specialty drugs, oncology, and ophthalmology services carry structurally higher economics than core distribution.

Management Outlook and Forward Catalysts

Management's strategic pivot toward high-value specialty platforms is accelerating, with $7.4 billion deployed for OneOncology and the concurrent decisions to divest MWI Animal Health and U.S. Consulting Services signaling a deliberate narrowing of the portfolio around human specialty healthcare. Long-term debt rose sharply to $12.2 billion from $7.5 billion at fiscal year-end, funded via $3.0 billion in new senior notes across five tranches and $1.5 billion in new term loans, with the company electing to prepay $500 million of the 2028 term loan by April 2026. The central investor debate entering Q3 centers on whether OneOncology's consolidated revenue contribution, which totaled only $313.7 million since the February close, can scale quickly enough to justify the leverage incurred, while bears will focus on negative operating cash flow of $967 million in the first half and the execution risk of simultaneously integrating RCA and OneOncology across complex physician practice models.